Skip to main content
An official website of the United States government

Pre-Cancer Atlas (PCA)

A tumor (yellow) is shown in the background. Components within the microenvironment are overlaid on the tumor, including a dendritic cell (pink), a T-cell (blue), a fibroblast (purple and pink), a natural killer cell (dark blue), a regulatory t cell (aqua), blood vessels (red), a macrophage cell (red with a yellow center), and a myeloid cell (green).

The Pre-cancer Atlas (PCA) Research Centers are part of the Human Tumor Atlas Network (HTAN). HTAN, an NCI-collaborative program, is constructing multi-dimensional atlases of the cellular, morphological, molecular, and spatial features of human cancers and their surrounding microenvironments over time.

The atlases being created by HTAN describe important changes during cancer progression, such as the transition of precancers to malignant tumors, the evolution of metastatic cancer, and the development of treatment resistance.

HTAN is supported by the NCI Division of Cancer Prevention (DCP), NCI Division of Biology (DCB), the NCI Division of Cancer Treatment and Diagnosis (DCTD), and the NCI Center for Strategic Science Initiatives (CSSI).

On This Page

  • All Heading 2s will automatically be pulled in to this list.
  • Do not edit the content on this template.

About Pre-Cancer Atlas

The Pre-cancer Atlas (PCA) Research Centers, along with the Human Tumor Atlas (HTA) Research Centers and a Data Coordinating Center (DCC), make up HTAN. Each PCA Research Center will create a 2D/3D precancer atlas of a pre-cancerous lesion, focusing on how it changes into cancer.

PCA Research Centers have three major tasks:

  • Collecting, processing, and labeling biospecimens.
  • Studying the molecular, cellular, and spatial details of the lesions.
  • Analyzing and modeling the data.

PCA Research Centers will collaborate with other components of HTAN to make the data and analytical tools available to the research community.

Grantee Details

PI Name Sort descending PI Organization Title Grant Number Program Official
Cremer, Miriam

Cleveland Clinic Lerner Com-Cwru
United States

Single Visit Clinical Validation of ScreenFire, a Low-Cost HPV Test: Efficacy and Cost Effectiveness (SCALE) 5R01CA266059-04 Vikrant Sahasrabuddhe, M.B.B.S., M.P.H., Dr.P.H.
Crowder, Sylvia

H. Lee Moffitt Cancer Ctr & Res Inst
United States

The MIND-BC Study: MIND diet for Breast cancer Cognition 1R01CA299480-01 Nancy J. Emenaker, Ph.D., RDN, LD, FAND
Crowder, Sylvia

H. Lee Moffitt Cancer Ctr & Res Inst
United States

The MIND-BC Study: MIND diet for Breast cancer Cognition 1R01CA299480-01 Nancy J. Emenaker, Ph.D., RDN, LD, FAND
Curtis, Amarinthia E

Spartanburg Regional Medical Center
United States

Upstate Carolina Consortium - Community Oncology Research Program 3UG1CA239762-06S1 Vanessa A. White, M.P.H.
Curtis, Amarinthia E

Spartanburg Regional Medical Center
United States

Upstate Carolina Consortium - Community Oncology Research Program 3UG1CA239762-06S1 Vanessa A. White, M.P.H.
Curtius, Kathleen M.

University Of California, San Diego
United States

Multiscale modeling of spatiotemporal evolution in Barrett's esophagus 5R01CA270235-03 Asad Umar, D.V.M., Ph.D.
Czerniak, Bogdan A

University Of Tx Md Anderson Can Ctr
United States

Mechanisms of Bladder Cancer Development and Its Therapeutic Vulnerabilities to Preventive and Interventive Therapy. 1P01CA296429-01A1 Howard L. Parnes, M.D.
Damaj, M. Imad

Virginia Commonwealth University
United States

Inhibition of NLRP3 inflammasome for the treatment of Chemotherapy-induced peripheral neuropathy 1R21CA296516-01 Rachel Altshuler, Ph.D.
Damaj, M. Imad

Virginia Commonwealth University
United States

Inhibition of NLRP3 inflammasome for the treatment of Chemotherapy-induced peripheral neuropathy 1R21CA296516-01 Rachel Altshuler, Ph.D.
Damaj, M. Imad

Virginia Commonwealth University
United States

Targeting Sphingosine-1-phosphate (S1P1) receptors for the treatment of Aromatase Inhibitors-induced Musculoskeletal Symptoms 5R01CA272147-03 Rachel Altshuler, Ph.D.
Damaj, M. Imad

Virginia Commonwealth University
United States

Targeting Sphingosine-1-phosphate (S1P1) receptors for the treatment of Aromatase Inhibitors-induced Musculoskeletal Symptoms 5R01CA272147-03 Rachel Altshuler, Ph.D.
Daniel-Macdougall, Carrie

University Of Tx Md Anderson Can Ctr
United States

Prebiotic diet intervention to enhance the microbiome and immunotherapy response in melanoma 5R01CA291965-02 Nancy J. Emenaker, Ph.D., RDN, LD, FAND
Dashwood, Roderick H

Texas A&M University Health Science Ctr
United States

Immunoepigenetic targeting of MHC regulators in FAP 5R01CA257559-03
Debes, Jose Daniel

University Of Minnesota
United States

Biomarkers for Early Detection of Hepatitis B-Related Hepatocellular Carcinoma in Hispanics 1R37CA297814-01 Sidney Fu, M.D.
Delaney, Joe R

Medical University Of South Carolina
United States

Biologic rationale of fallopian tube removal to prevent uterine serous carcinoma 1R21CA292343-01A1 Goli Samimi, Ph.D., M.P.H.